Streetbeat News

Analyst Ratings

KNTE

Wedbush analyst David Nierengarten has downgraded Kinnate Biopharma from Outperform to Neutral and lowered the price target from $14 to $2.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:58 am

SPSC

Needham analyst Scott Berg has reiterated a 'Buy' rating on SPS Commerce (NASDAQ:SPSC) and maintained a price target of $205.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:56 am

AAPL

Barclays analyst Tim Long has reiterated an Equal-Weight rating on Apple (NASDAQ:AAPL) and maintained a price target of $167.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:37 am

SUI

Barclays analyst Anthony Powell maintains an Overweight rating on Sun Communities (NYSE:SUI) but lowers the price target from $158 to $157.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:35 am

SFIX

Barclays analyst Trevor Young has maintained an Equal-Weight rating on Stitch Fix (NASDAQ:SFIX) and lowered the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:33 am

CAMT

Barclays analyst Tom O'Malley has maintained an Equal-Weight rating on Camtek (NASDAQ:CAMT) and raised the price target from $46 to $55.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:32 am

AKRO

Cantor Fitzgerald analyst Prakhar Agrawal has initiated coverage on Akero Therapeutics (NASDAQ:AKRO) with an Overweight rating and a price target of $69.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:31 am

PRAX

Truist Securities analyst Joon Lee has initiated coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:30 am

AUR

TD Cowen analyst Jeffrey Osborne has initiated coverage on Aurora Innovation (NASDAQ:AUR) with a Market Perform rating and a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:26 am

RCL

Truist Securities analyst Patrick Scholes has upgraded Royal Caribbean Gr (NYSE:RCL) from Hold to Buy and raised the price target from $115 to $137.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 10:23 am